[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543966":3},{"organization":4,"outcomesModule":7,"designInfo":48,"detailedDescription":59,"studyPopulation":47,"armGroups":60,"interventions":73,"overallOfficials":82,"centralContacts":87,"locations":97,"responsibleParty":432,"collaborators":47,"id":434,"slug":47,"hasResults":435,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":47,"eligibilityCriteria":439,"healthyVolunteers":435,"sex":440,"minAge":441,"maxAge":47,"enrollmentInfo":442,"targetDuration":47,"studyType":445,"phases":446,"briefSummary":448,"conditions":449,"keywords":451,"overallStatus":100,"whyStopped":47,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":464},{"fullName":5,"class":6},"Supergene, LLC","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":47},[9],{"measure":10,"description":11,"timeFrame":12},"Composite of death from any cause or hemodynamic collapse or recurrent PE","The efficacy is evaluated in terms of the number of death from any cause or hemodynamic collapse or recurrent PE","within 30 days",[14,18,21,22,25,28,31,35,38,41,44],{"measure":15,"description":16,"timeFrame":17},"Right\u002Fleft ventricular (RV\u002FLV) end-diastolic diameter ratio","The efficacy is evaluated in terms of the RV\u002FLV end-diastolic diameter ratio according to echocardiography","within 24 hours",{"measure":19,"description":20,"timeFrame":17},"RV\u002FLV end-diastolic diameter ratio","The efficacy is evaluated in terms of the RV\u002FLV end-diastolic diameter ratio according to computed tomography pulmonary angiography (CTPA)",{"measure":19,"description":16,"timeFrame":12},{"measure":23,"description":24,"timeFrame":17},"Right ventricular (RV) end-diastolic volume","The efficacy is evaluated in terms of the RV end-diastolic volume according to CTPA",{"measure":26,"description":27,"timeFrame":17},"Qanadli index","The efficacy is evaluated in terms of Qanadli index according to CTPA in points from 0 to 40, where 0 points - absence of thrombotic masses in the pulmonary artery, 40 points - complete occlusion of the pulmonary artery",{"measure":29,"description":30,"timeFrame":17},"Systolic pulmonary artery pressure","The efficacy is evaluated in terms of the systolic pulmonary artery pressure according to echocardiography",{"measure":32,"description":33,"timeFrame":34},"In hospital death from all causes (assessed up to day 7)","The efficacy is evaluated in terms of the in hospital death from all causes (assessed up to day 7)","In hospital period (assessed up to day 7)",{"measure":36,"description":37,"timeFrame":12},"Death from all causes","The efficacy is evaluated in terms of the death from all causes",{"measure":39,"description":40,"timeFrame":12},"Safety endpoint - hemorrhagic stroke","The efficacy is evaluated in terms of the hemorrhagic stroke",{"measure":42,"description":43,"timeFrame":12},"Safety endpoint - BARC type 3 and 5 bleeding","The efficacy is evaluated in terms of the Bleeding Academic Research Consortium definitions, where type 3a is an overt bleeding with hemoglobin drop of 3 to 5 g\u002FdL and any transfusion with overt bleeding; type 3b is a bleeding requiring surgical intervention or intravenous vasoactive agents; type 3c is an intracranial hemorrhage; type 5 is fatal bleeding.",{"measure":45,"description":46,"timeFrame":12},"Safety endpoint - number and severity of adverse events (AEs) and serious AEs in organs and systems","The efficacy is evaluated in terms of the number and severity of AEs and serious AEs in organs and systems",null,{"allocation":49,"interventionModel":50,"interventionModelDescription":51,"primaryPurpose":52,"observationalModel":47,"timePerspective":47,"maskingInfo":53},"RANDOMIZED","PARALLEL","At clinical sites patients will be equally randomized into two groups to receive non-immunogenic recombinant staphylokinase or placebo.\n\nNon-immunogenic recombinant staphylokinase or placebo will be administered intravenously at a dose of 15 mg as a single bolus for 10-15 seconds. All patients will be examined for 30 days.","TREATMENT",{"masking":54,"maskingDescription":55,"whoMasked":56},"DOUBLE","Neither patient nor investigator knows treatment assignment. All eligible patients will be randomized in two equal groups for administration of non-immunogenic recombinant staphylokinase or placebo.",[57,58],"PARTICIPANT","INVESTIGATOR","For patients with massive PE thrombolysis can be life-saving and may reduce a pulmonary obstruction, pulmonary hypertension, and right ventricle dysfunction. Efficacy of the thrombolytic therapy has been proven in patients with high-risk pulmonary embolism accompanied by shock or systemic hypotension. However, the question of whether thrombolytic therapy can improve the clinical outcome of hemodynamically stable patients, i.e. with PE of intermediate high-risk, still remains controversial.\n\nIn PEITHO trial tenecteplase, administered as a single bolus at a dose of 30-50 mg depending on body weight was compared with a placebo in patients with intermediate high-risk PE with right ventricular dysfunction. Efficacy of tenecteplase was combined with a significant (6.3%) risk of hemorrhagic stroke, which did not allow tenecteplase to be included in the list of recommended thrombolytics for PE treatment.\n\nPEITHO-3 trial has now begun, in which patients with intermediate high-risk PE are given a reduced dose of alteplase (0.6 mg\u002Fkg infusion with the total dose not exceeding 50 mg) compared with placebo.\n\nStaphylokinase is a thrombolytic agent with high biological activity. Amino acid substitutions - including Lys74Ala, Glu75Ala, and Arg77Ala - resulted in a more than 200-times reduction in titres of neutralising antistaphylokinase IgGs in patients with ST-elevation myocardial infarction. In FORPE trial non-immunogenic recombinant staphylokinase was non-inferior as compared with alteplase in patients with high-risk massive PE.\n\nThe main objectives of this study: to assess the efficacy, safety and possible adverse events of the non-immunogenic recombinant staphylokinase with its single bolus administration in normotensive patients with intermediate high-risk PE in comparison with placebo.",[61,67],{"label":62,"type":63,"description":64,"interventionNames":65},"Non-immunogenic recombinant staphylokinase","EXPERIMENTAL","lyophilisate for preparation of a solution for intravenous administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, intravenously as a quick single bolus injection for 10-15 seconds, regardless of body weight.",[66],"Drug: Non-immunogenic recombinant staphylokinase",{"label":68,"type":69,"description":70,"interventionNames":71},"Placebo","PLACEBO_COMPARATOR","15 mg of placebo reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds",[72],"Drug: Placebo",[74,80],{"type":75,"name":62,"description":76,"armGroupLabels":77,"otherNames":78},"DRUG","15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds",[62],[79],"Fortelyzin®",{"type":75,"name":68,"description":70,"armGroupLabels":81,"otherNames":47},[68],[83],{"name":84,"affiliation":85,"role":86},"Sergey N. Tereschenko, MD, PhD","National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","PRINCIPAL_INVESTIGATOR",[88,94],{"name":89,"role":90,"phone":91,"phoneExt":92,"email":93},"Sergey S. Markin, MD, PhD","CONTACT","(906) 796-89-06","+7","ssmarkin2153@mail.ru",{"name":84,"role":90,"phone":95,"phoneExt":92,"email":96},"(495) 150-44-19","stereschenko@yandex.ru",[98,118,134,145,159,174,189,203,220,235,247,259,272,283,298,308,321,330,345,357,372,387,402,417],{"facility":99,"status":100,"city":101,"state":102,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":111,"contacts":112},"RZD Medicine hospital","RECRUITING","Barnaul","Altayskiy Kray","656038","Russia","RU",{"type":107,"coordinates":108},"Point",[109,110],83.72786,53.36199,{"lat":110,"lon":109},[113,117],{"name":114,"role":90,"phone":115,"phoneExt":92,"email":116},"Mikhail I. Neimark, MD, PhD","(3852) 757-966","mineimark@asmu.ru",{"name":114,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":119,"status":100,"city":120,"state":121,"zip":122,"country":104,"countryCode":105,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"V.F. Dolgopolov Vyselki Central District Hospital","Vyselki","Krasnodarskiy Kray","353100",{"type":107,"coordinates":124},[125,126],39.65741,45.58058,{"lat":126,"lon":125},[129,133],{"name":130,"role":90,"phone":131,"phoneExt":92,"email":132},"Valerii V. Makukhin, PhD","(86199) 123-53","makuhinv@mail.ru",{"name":130,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":135,"status":136,"city":137,"state":138,"zip":139,"country":104,"countryCode":105,"cosmosGeoPoint":140,"geoPoint":144,"contacts":47},"Asinovskaya District Hospital","COMPLETED","Asino","Tomsk Oblast","636840",{"type":107,"coordinates":141},[142,143],86.15518,56.99918,{"lat":143,"lon":142},{"facility":146,"status":100,"city":147,"state":47,"zip":148,"country":104,"countryCode":105,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Belgorod Regional Clinical Hospital of St. Joseph","Belgorod","308007",{"type":107,"coordinates":150},[151,152],36.58091,50.60343,{"lat":152,"lon":151},[155,158],{"name":156,"role":90,"phone":47,"phoneExt":47,"email":157},"Sergei L Konstantinov, MD","konstantinov5@yandex.ru",{"name":156,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":160,"status":100,"city":161,"state":47,"zip":162,"country":104,"countryCode":105,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Kuzbass Cardiology center","Kemerovo","650002",{"type":107,"coordinates":164},[165,166],86.10435,55.35417,{"lat":166,"lon":165},[169,173],{"name":170,"role":90,"phone":171,"phoneExt":47,"email":172},"Vasilii V. Kashtalap, MD, PhD","+7 (3842) 64-22-41","v_kash@mail.ru",{"name":170,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":175,"status":100,"city":176,"state":47,"zip":177,"country":104,"countryCode":105,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"Center of Neurology and Cardiology","Kirov","610035",{"type":107,"coordinates":179},[180,181],49.65783,58.59809,{"lat":181,"lon":180},[184,188],{"name":185,"role":90,"phone":186,"phoneExt":92,"email":187},"Oleg V. Solovyev, PhD","(8332) 56-35-74","ckn@medkirov.ru",{"name":185,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":190,"status":100,"city":191,"state":47,"zip":192,"country":104,"countryCode":105,"cosmosGeoPoint":193,"geoPoint":197,"contacts":198},"Regional Clinical Hospital №2","Krasnodar","350012",{"type":107,"coordinates":194},[195,196],38.98178,45.04534,{"lat":196,"lon":195},[199,202],{"name":200,"role":90,"phone":201,"phoneExt":92,"email":132},"Tamara A. Chirva, MD","(861) 222-000-2",{"name":200,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":204,"status":100,"city":205,"state":47,"zip":206,"country":104,"countryCode":105,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"Lipetsk City Hospital No. 4 \"Lipetsk-Med\"","Lipetsk","398006",{"type":107,"coordinates":208},[209,210],39.55151,52.5876,{"lat":210,"lon":209},[213,217,219],{"name":214,"role":90,"phone":215,"phoneExt":92,"email":216},"Roman S. Ovchinnikov, PhD","(474) 225-81-00","romzec@yandex.ru",{"name":218,"role":90,"phone":47,"phoneExt":47,"email":47},"Alexander V. Lubavin, PhD",{"name":214,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":221,"status":100,"city":222,"state":47,"zip":223,"country":104,"countryCode":105,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"F.I. Inozemtsev City Clinical Hospital","Moscow","105187",{"type":107,"coordinates":225},[226,227],37.61781,55.75204,{"lat":227,"lon":226},[230,234],{"name":231,"role":90,"phone":232,"phoneExt":92,"email":233},"Evgenia V. Tavlueva, PhD","(495) 366-77-19","tavlev1@mail.ru",{"name":231,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":236,"status":100,"city":222,"state":47,"zip":237,"country":104,"countryCode":105,"cosmosGeoPoint":238,"geoPoint":240,"contacts":241},"Moscow Multidisciplinary Clinical Center \"Kommunarka\"","108814",{"type":107,"coordinates":239},[226,227],{"lat":227,"lon":226},[242,246],{"name":243,"role":90,"phone":244,"phoneExt":92,"email":245},"Anastasia Yu Lebedeva, PhD","(495) 744-07-03","alebedeva-md@yandex.ru",{"name":243,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":248,"status":100,"city":222,"state":47,"zip":249,"country":104,"countryCode":105,"cosmosGeoPoint":250,"geoPoint":252,"contacts":253},"S.S. Yudin City Clinical Hospital","115446",{"type":107,"coordinates":251},[226,227],{"lat":227,"lon":226},[254,258],{"name":255,"role":90,"phone":256,"phoneExt":47,"email":257},"Bogdan B Orlov, MD, PhD","7 (499) 612-45-66","bborlov@mail.ru",{"name":255,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":260,"status":100,"city":222,"state":47,"zip":261,"country":104,"countryCode":105,"cosmosGeoPoint":262,"geoPoint":264,"contacts":265},"V.M. Buyanov City Clinical Hospital","115516",{"type":107,"coordinates":263},[226,227],{"lat":227,"lon":226},[266,270],{"name":267,"role":90,"phone":268,"phoneExt":92,"email":269},"Yury V. Gavrilov, PhD","(495) 321-54-92","gavrilovyv@zdrav.mos.ru",{"name":271,"role":86,"phone":47,"phoneExt":47,"email":47},"Yury V. Gavrilov, Gavrilov",{"facility":273,"status":100,"city":222,"state":47,"zip":47,"country":104,"countryCode":105,"cosmosGeoPoint":274,"geoPoint":276,"contacts":277},"S.P. Botkin City Clinical Hospital",{"type":107,"coordinates":275},[226,227],{"lat":227,"lon":226},[278,282],{"name":279,"role":90,"phone":280,"phoneExt":92,"email":281},"Yuri V. Karabach, PhD","(499) 490-03-03","yu.karabach@ya.ru",{"name":279,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":284,"status":100,"city":285,"state":47,"zip":286,"country":104,"countryCode":105,"cosmosGeoPoint":287,"geoPoint":291,"contacts":292},"N.A. Semashko Nizhny Novgorod Regional Clinical Hospital","Nizhny Novgorod","603093",{"type":107,"coordinates":288},[289,290],44.00205,56.32867,{"lat":290,"lon":289},[293,297],{"name":294,"role":90,"phone":295,"phoneExt":92,"email":296},"Galina V. Kovakeva, PhD","(831) 436-40-01","kogaval@mail.ru",{"name":294,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":299,"status":300,"city":301,"state":47,"zip":302,"country":104,"countryCode":105,"cosmosGeoPoint":303,"geoPoint":307,"contacts":47},"N.N. Burdenko Penza Regional Clinical hospital","WITHDRAWN","Penza","440026",{"type":107,"coordinates":304},[305,306],45.01075,53.19568,{"lat":306,"lon":305},{"facility":309,"status":100,"city":301,"state":47,"zip":310,"country":104,"countryCode":105,"cosmosGeoPoint":311,"geoPoint":313,"contacts":314},"G.A. Zakharyin Clinical hospital №6","440071",{"type":107,"coordinates":312},[305,306],{"lat":306,"lon":305},[315,319],{"name":316,"role":90,"phone":317,"phoneExt":92,"email":318},"Elena S. Panina, PhD","(8412) 98-33-55","panina.es@mail.ru",{"name":320,"role":86,"phone":47,"phoneExt":47,"email":47},"Elena S. panina, PhD",{"facility":322,"status":300,"city":323,"state":47,"zip":324,"country":104,"countryCode":105,"cosmosGeoPoint":325,"geoPoint":329,"contacts":47},"City Clinical Hospital №4","Perm","614107",{"type":107,"coordinates":326},[327,328],56.25017,58.01046,{"lat":328,"lon":327},{"facility":331,"status":100,"city":332,"state":47,"zip":333,"country":104,"countryCode":105,"cosmosGeoPoint":334,"geoPoint":338,"contacts":339},"City Hospital No. 26","Saint Petersburg","196247",{"type":107,"coordinates":335},[336,337],30.31413,59.93863,{"lat":337,"lon":336},[340,344],{"name":341,"role":90,"phone":342,"phoneExt":92,"email":343},"Dmitry A. Svirido, PhD","(812) 415-18-88","teratology@mail.ru",{"name":341,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":346,"status":100,"city":332,"state":47,"zip":347,"country":104,"countryCode":105,"cosmosGeoPoint":348,"geoPoint":350,"contacts":351},"City Hospital No. 15","198205",{"type":107,"coordinates":349},[336,337],{"lat":337,"lon":336},[352,356],{"name":353,"role":90,"phone":354,"phoneExt":92,"email":355},"Boris M. Goloschekin, PhD","(812) 338-96-98","bgoloschekin@yandex.ru",{"name":353,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":358,"status":100,"city":359,"state":47,"zip":360,"country":104,"countryCode":105,"cosmosGeoPoint":361,"geoPoint":365,"contacts":366},"V.P. Polyakov Samara Regional Clinical Cardiology Dispensary","Samara","443070",{"type":107,"coordinates":362},[363,364],50.13553,53.20767,{"lat":364,"lon":363},[367,371],{"name":368,"role":90,"phone":369,"phoneExt":47,"email":370},"Dmitrii V Duplyakov, MD, PhD","8 (846) 373-70-63","duplyakov@yahoo.com",{"name":368,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":373,"status":100,"city":374,"state":47,"zip":375,"country":104,"countryCode":105,"cosmosGeoPoint":376,"geoPoint":380,"contacts":381},"Tomsk regional cilinical hospital","Tomsk","634063",{"type":107,"coordinates":377},[378,379],84.98216,56.50049,{"lat":379,"lon":378},[382,386],{"name":383,"role":90,"phone":384,"phoneExt":92,"email":385},"Sergei I. Antipov, PhD","(382) 263-00-63","sergey.antipov1974@gmail.com",{"name":383,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":388,"status":100,"city":389,"state":47,"zip":390,"country":104,"countryCode":105,"cosmosGeoPoint":391,"geoPoint":395,"contacts":396},"Tver Regional Clinical Hospital","Tver'","170036",{"type":107,"coordinates":392},[393,394],35.90057,56.85836,{"lat":394,"lon":393},[397,401],{"name":398,"role":90,"phone":399,"phoneExt":92,"email":400},"Vladimir V. Bobkov, PhD","(4822)36-40-93","vladibo73@gmail.com",{"name":398,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":403,"status":100,"city":404,"state":47,"zip":405,"country":104,"countryCode":105,"cosmosGeoPoint":406,"geoPoint":410,"contacts":411},"Ufa Emergency City Hospital","Ufa","450092",{"type":107,"coordinates":407},[408,409],55.96779,54.74306,{"lat":409,"lon":408},[412,416],{"name":413,"role":90,"phone":414,"phoneExt":92,"email":415},"Marat S. Kashaev, PhD","(347) 291-29-96","mkashaev@gmail.com",{"name":413,"role":86,"phone":47,"phoneExt":47,"email":47},{"facility":418,"status":100,"city":419,"state":47,"zip":420,"country":104,"countryCode":105,"cosmosGeoPoint":421,"geoPoint":425,"contacts":426},"City Clinical Hospital of Emergency medicine №25","Volgograd","400138",{"type":107,"coordinates":422},[423,424],44.4976,48.71378,{"lat":424,"lon":423},[427,431],{"name":428,"role":90,"phone":429,"phoneExt":92,"email":430},"Eduard A. Ponomarev, PhD","(8442) 58-16-61","ponomarev67@mail.ru",{"name":428,"role":86,"phone":47,"phoneExt":47,"email":47},{"type":433,"investigatorFullName":47,"investigatorTitle":47,"investigatorAffiliation":47,"oldNameTitle":47,"oldOrganization":47},"SPONSOR","100543966",false,"NCT06362746","Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism","Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Efficacy and Safety of a Single Bolus Administration of Non-immunogenic Recombinant Staphylokinase in Patients With Intermediate High-risk Pulmonary Embolism (FORPE-2)","Inclusion Criteria:\n\n* Men and women aged 18 and over.\n* Verified diagnosis of intermediate high-risk PE using CTPA, no more than two weeks from the symptoms onset.\n* RV dysfunction, defined as a RV\u002FLV ventricular end-diastolic diameter ratio more than 1.0 assessed by CTPA.\n* Increased risk of early death or hemodynamic collapse, defined by one of the following criteria:\n\n  1. systolic blood pressure less than 110 mm Hg, but not less than 90 mm Hg for more than 15 minutes;\n  2. respiratory rate more than 20 per minute or SpO2 less than 90% without oxygen support;\n  3. chronic heart failure with left ventricular ejection fraction less than 40%.\n* Serum troponin I level more than 14 pg\u002FmL in patients under 75 years, and more than 45 pg\u002FmL in patients aged 75 years or older.\n* Patient consent to use reliable contraceptive methods throughout the study and for 3 weeks after:\n\n  * women who have a negative pregnancy test and use the following contraceptives: intrauterine devices, oral contraceptives, contraceptive patch, prolonged injectable contraceptives, double barrier method of contraception. Women who are not fertile can also take part in the study (documented conditions: hysterectomy, tubal ligation, infertility, menopause for more than 1 year);\n  * men using barrier contraception. The study may also involve men who are not fertile (documented conditions: vasectomy, infertility).\n* Availability of signed and dated informed consent of the patient to participate in the study.\n\nExclusion Criteria:\n\n* High-risk PE with hemodynamic instability.\n* Increased risk of bleeding:\n\n  * extensive bleeding at present or within the previous 6 months;\n  * intracranial (including subarachnoid) hemorrhage at present or in history;\n  * hemorrhagic stroke within the last 6 months;\n  * a history of diseases of the central nervous system (including neoplasms, aneurysms);\n  * intracranial or spinal surgical interventions within the last 2 months;\n  * major surgery or major trauma within the previous 4 weeks;\n  * recent puncture of an incompressible blood vessel (eg, subclavian or jugular vein);\n  * severe liver disease, including liver failure, cirrhosis, portal hypertension (including esophageal varices) and active hepatitis;\n  * confirmed gastric or duodenal ulcer within the last 3 months;\n  * neoplasm with an increased risk of bleeding;\n  * simultaneous administration of Dabigatran without prior administration of idarucizumab;\n  * arterial aneurysms, developmental defects of arteries \u002F veins;\n  * acute pancreatitis;\n  * bacterial endocarditis, pericarditis;\n  * suspicion of aortic dissecting aneurysm;\n  * any other conditions, in the opinion of the investigator, associated with a high risk of bleeding.\n* Lactation, pregnancy.\n* Known hypersensitivity to the non-immunogenic recombinant staphylokinase.","ALL","18 Years",{"count":443,"type":444},486,"ESTIMATED","INTERVENTIONAL",[447],"PHASE3","Objective: to evaluate the efficacy and safety of the non-immunogenic recombinant staphylokinase with its single bolus administration in comparison with placebo in normotensive patients with intermediate high-risk pulmonary embolism (PE)",[450],"Pulmonary Embolism",[452,453,454],"Intermediate high-risk pulmonary embolism","Fibrinolysis","Recombinant Non-immunogenic Staphylokinase","2025-11-27",{"date":457,"type":458},"2025-12-05","ACTUAL",{"date":460,"type":458},"2024-05-23",{"date":462,"type":444},"2028-12-01",{"name":5,"class":6},24]